Last reviewed · How we verify
Cipher Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Spinosad Topical | Spinosad Topical | marketed | Natural insecticide | Nicotinic acetylcholine receptors; GABA-gated chloride channels | Dermatology | |
| CIP-Isotretinoin | CIP-Isotretinoin | phase 3 | Retinoid | Retinoid acid receptors (RAR, RXR) | Oncology |
Therapeutic area mix
- Dermatology · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Actavis Inc. · 1 shared drug class
- Army Medical University, China · 1 shared drug class
- Bausch Health Americas, Inc. · 1 shared drug class
- Center for Sight Las Vegas · 1 shared drug class
- Centro Dermatológico Dr. Ladislao de la Pascua · 1 shared drug class
- Dr. Emmy Graber · 1 shared drug class
- Dr. Reddy's Laboratories Limited · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Cipher Pharmaceuticals Inc.:
- Cipher Pharmaceuticals Inc. pipeline updates — RSS
- Cipher Pharmaceuticals Inc. pipeline updates — Atom
- Cipher Pharmaceuticals Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cipher Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cipher-pharmaceuticals-inc. Accessed 2026-05-14.